262 related articles for article (PubMed ID: 8818571)
1. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats.
Cundy KC; Bidgood AM; Lynch G; Shaw JP; Griffin L; Lee WA
Drug Metab Dispos; 1996 Jul; 24(7):745-52. PubMed ID: 8818571
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.
Cundy KC; Li ZH; Hitchcock MJ; Lee WA
Drug Metab Dispos; 1996 Jul; 24(7):738-44. PubMed ID: 8818570
[TBL] [Abstract][Full Text] [Related]
3. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits.
Cundy KC; Lynch G; Shaw JP; Hitchcock MJ; Lee WA
Curr Eye Res; 1996 May; 15(5):569-76. PubMed ID: 8670758
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.
Cundy KC; Barditch-Crovo P; Petty BG; Ruby A; Redpath M; Jaffe HS; Lietman PS
Antimicrob Agents Chemother; 1999 Feb; 43(2):271-7. PubMed ID: 9925517
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs.
Oliyai R; Arimilli MN; Jones RJ; Lee WA
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1411-4. PubMed ID: 11563033
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and metabolism of cidofovir following topical administration to rabbits.
Cundy KC; Lynch G; Lee WA
Antiviral Res; 1997 Jul; 35(2):113-22. PubMed ID: 9217248
[TBL] [Abstract][Full Text] [Related]
7. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits.
Cundy KC; Li ZH; Lee WA
Drug Metab Dispos; 1996 Mar; 24(3):315-21. PubMed ID: 8820422
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
9. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.
Bischofberger N; Hitchcock MJ; Chen MS; Barkhimer DB; Cundy KC; Kent KM; Lacy SA; Lee WA; Li ZH; Mendel DB
Antimicrob Agents Chemother; 1994 Oct; 38(10):2387-91. PubMed ID: 7840575
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
Smee DF; Bailey KW; Sidwell RW
Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects.
Wachsman M; Petty BG; Cundy KC; Jaffe HS; Fisher PE; Pastelak A; Lietman PS
Antiviral Res; 1996 Mar; 29(2-3):153-61. PubMed ID: 8739595
[TBL] [Abstract][Full Text] [Related]
12. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Ho HT; Woods KL; Bronson JJ; De Boeck H; Martin JC; Hitchcock MJ
Mol Pharmacol; 1992 Jan; 41(1):197-202. PubMed ID: 1310143
[TBL] [Abstract][Full Text] [Related]
13. Enhanced chemical stability of the intracellular prodrug, 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, relative to its parent compound, cidofovir.
Oliyai R; Lee WA; Visor GC; Yuan LC
Int J Pharm; 1999 Mar; 179(2):257-65. PubMed ID: 10053218
[TBL] [Abstract][Full Text] [Related]
14. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
Aduma P; Connelly MC; Srinivas RV; Fridland A
Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
[TBL] [Abstract][Full Text] [Related]
15. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.
Mendel DB; Cihlar T; Moon K; Chen MS
Antimicrob Agents Chemother; 1997 Mar; 41(3):641-6. PubMed ID: 9056007
[TBL] [Abstract][Full Text] [Related]
16. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
Stals FS; Zeytinoglu A; Havenith M; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1993 Feb; 37(2):218-23. PubMed ID: 8383939
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis.
Taskintuna I; Rahhal FM; Capparelli EV; Cundy KC; Freeman WR
J Ocul Pharmacol Ther; 1998 Apr; 14(2):147-51. PubMed ID: 9572540
[TBL] [Abstract][Full Text] [Related]
18. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.
Roy CJ; Baker R; Washburn K; Bray M
Antimicrob Agents Chemother; 2003 Sep; 47(9):2933-7. PubMed ID: 12936997
[TBL] [Abstract][Full Text] [Related]
19. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
Lalezari JP; Stagg RJ; Jaffe HS; Hitchcock MJ; Drew WL
Adv Exp Med Biol; 1996; 394():105-15. PubMed ID: 8815677
[No Abstract] [Full Text] [Related]
20. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Cundy KC; Petty BG; Flaherty J; Fisher PE; Polis MA; Wachsman M; Lietman PS; Lalezari JP; Hitchcock MJ; Jaffe HS
Antimicrob Agents Chemother; 1995 Jun; 39(6):1247-52. PubMed ID: 7574510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
